These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
196 related articles for article (PubMed ID: 21284704)
21. Kava and kava hepatotoxicity: requirements for novel experimental, ethnobotanical and clinical studies based on a review of the evidence. Teschke R; Qiu SX; Xuan TD; Lebot V Phytother Res; 2011 Sep; 25(9):1263-74. PubMed ID: 21442674 [TBL] [Abstract][Full Text] [Related]
22. Regulatory causality evaluation methods applied in kava hepatotoxicity: are they appropriate? Teschke R; Wolff A Regul Toxicol Pharmacol; 2011 Feb; 59(1):1-7. PubMed ID: 20854865 [TBL] [Abstract][Full Text] [Related]
26. German Kava Ban Lifted by Court: The Alleged Hepatotoxicity of Kava (Piper methysticum) as a Case of Ill-Defined Herbal Drug Identity, Lacking Quality Control, and Misguided Regulatory Politics. Kuchta K; Schmidt M; Nahrstedt A Planta Med; 2015 Dec; 81(18):1647-53. PubMed ID: 26695707 [TBL] [Abstract][Full Text] [Related]
28. Hepatic injury due to traditional aqueous extracts of kava root in New Caledonia. Russmann S; Barguil Y; Cabalion P; Kritsanida M; Duhet D; Lauterburg BH Eur J Gastroenterol Hepatol; 2003 Sep; 15(9):1033-6. PubMed ID: 12923378 [TBL] [Abstract][Full Text] [Related]
30. Tradition and toxicity: evidential cultures in the kava safety debate. Baker JD Soc Stud Sci; 2011 Jun; 41(3):361-84. PubMed ID: 21879526 [TBL] [Abstract][Full Text] [Related]
31. Toxic hepatitis after consumption of traditional kava preparation. Christl SU; Seifert A; Seeler D J Travel Med; 2009; 16(1):55-6. PubMed ID: 19192130 [TBL] [Abstract][Full Text] [Related]
32. A less than Pacific odyssey: the use of kava. Mack RB N C Med J; 1999; 60(2):91-3. PubMed ID: 10344133 [No Abstract] [Full Text] [Related]
33. [Kava, kavapyrones and toxic liver injury]. Teschke R Z Gastroenterol; 2003 May; 41(5):395-404. PubMed ID: 12772052 [TBL] [Abstract][Full Text] [Related]
34. Kava for the treatment of generalised anxiety disorder (K-GAD): study protocol for a randomised controlled trial. Savage KM; Stough CK; Byrne GJ; Scholey A; Bousman C; Murphy J; Macdonald P; Suo C; Hughes M; Thomas S; Teschke R; Xing C; Sarris J Trials; 2015 Nov; 16():493. PubMed ID: 26527536 [TBL] [Abstract][Full Text] [Related]
35. Kava for generalised anxiety disorder: A 16-week double-blind, randomised, placebo-controlled study. Sarris J; Byrne GJ; Bousman CA; Cribb L; Savage KM; Holmes O; Murphy J; Macdonald P; Short A; Nazareth S; Jennings E; Thomas SR; Ogden E; Chamoli S; Scholey A; Stough C Aust N Z J Psychiatry; 2020 Mar; 54(3):288-297. PubMed ID: 31813230 [TBL] [Abstract][Full Text] [Related]
36. Kava hepatotoxicity: comparative study of two structured quantitative methods for causality assessment. Teschke R; Fuchs J; Bahre R; Genthner A; Wolff A J Clin Pharm Ther; 2010 Oct; 35(5):545-63. PubMed ID: 20831679 [TBL] [Abstract][Full Text] [Related]
37. [Treatment with Kava--the root to ocombat stress]. Müller B; Komorek R Wien Med Wochenschr; 1999; 149(8-10):197-201. PubMed ID: 10483680 [TBL] [Abstract][Full Text] [Related]
38. Kava hepatotoxicity: regulatory data selection and causality assessment. Teschke R; Wolff A Dig Liver Dis; 2009 Dec; 41(12):891-901. PubMed ID: 19477698 [TBL] [Abstract][Full Text] [Related]
39. Kava-kava and anxiety: growing knowledge about the efficacy and safety. Bilia AR; Gallon S; Vincieri FF Life Sci; 2002 Apr; 70(22):2581-97. PubMed ID: 12269386 [TBL] [Abstract][Full Text] [Related]
40. [Acute hepatitis due to kava-kava and St John's Wort: an immune-mediated mechanism?]. Teschke R Dtsch Med Wochenschr; 2006 Aug; 131(34-35):1880-1; author reply 1882-3. PubMed ID: 16915552 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]